Viewing Study NCT02142192


Ignite Creation Date: 2025-12-24 @ 3:25 PM
Ignite Modification Date: 2026-01-04 @ 11:55 AM
Study NCT ID: NCT02142192
Status: TERMINATED
Last Update Posted: 2024-06-03
First Post: 2014-05-16
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Natalizumab Subcutaneous Immunogenicity and Safety Study
Sponsor: Biogen
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module